探索性代谢组学研究，旨在寻找基于血液的生物标志物，作为结直肠癌的潜在筛查手段。
Exploratory metabolomic study to identify blood-based biomarkers as a potential screen for colorectal cancer.
机构信息
Department of Clinical Pharmacy, School of Pharmacy, University of Southern California, CA, USA.
出版信息
Mol Omics. 2019 Feb 11;15(1):21-29. doi: 10.1039/c8mo00158h.
INTRODUCTION
colorectal cancer (CRC) continues to be difficult to diagnose due to the lack of reliable and predictive biomarkers.
OBJECTIVE
to identify blood-based biomarkers that can be used to distinguish CRC cases from controls.
METHODS
a workflow for untargeted followed by targeted metabolic profiling was conducted on the plasma samples of 26 CRC cases and ten healthy volunteers (controls) using liquid chromatography-mass spectrometry (LCMS). The data acquired in the untargeted scan was processed and analyzed using MarkerView™ software. The significantly different ions that distinguish CRC cases from the controls were identified using a mass-based human metabolome search. The result was further used to inform the targeted scan workflow.
RESULTS
the untargeted scan yielded putative biomarkers some of which were related to the folate-dependent one-carbon metabolism (FOCM). Analysis of the targeted scan found the plasma levels of nine FOCM metabolites to be significantly different between cases and controls. The classification models of the cases and controls, in both the targeted and untargeted approaches, each yielded a 97.2% success rate after cross-validation.
CONCLUSION
we have identified plasma metabolites with screening potential to discriminate between CRC cases and controls.
简介
由于缺乏可靠和可预测的生物标志物，结直肠癌（CRC）的诊断仍然具有挑战性。
目的
确定可用于区分 CRC 病例和对照的基于血液的生物标志物。
方法
使用液相色谱-质谱联用（LCMS）对 26 例 CRC 病例和 10 名健康志愿者（对照）的血浆样本进行非靶向和靶向代谢物分析的工作流程。使用 MarkerView™软件对非靶向扫描中获得的数据进行处理和分析。使用基于质量的人类代谢组搜索来鉴定区分 CRC 病例和对照的差异显著离子。该结果进一步用于告知靶向扫描工作流程。
结果
非靶向扫描产生了一些假定的生物标志物，其中一些与叶酸依赖性一碳代谢（FOCM）有关。靶向扫描分析发现，病例和对照组之间九个 FOCM 代谢物的血浆水平存在显著差异。在靶向和非靶向方法中，病例和对照组的分类模型在交叉验证后均产生了 97.2%的成功率。
结论
我们已经确定了具有筛选潜力的血浆代谢物，可用于区分 CRC 病例和对照。
Zotero 插件